Acasti Pharma Stock Current Liabilities
ACSTDelisted Stock | USD 3.37 0.01 0.30% |
Acasti Pharma fundamentals help investors to digest information that contributes to Acasti Pharma's financial success or failures. It also enables traders to predict the movement of Acasti Stock. The fundamental analysis module provides a way to measure Acasti Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Acasti Pharma stock.
Acasti |
Acasti Pharma Company Current Liabilities Analysis
Acasti Pharma's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Acasti Pharma Current Liabilities | 1.14 M |
Most of Acasti Pharma's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Acasti Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
CompetitionIn accordance with the recently published financial statements, Acasti Pharma has a Current Liabilities of 1.14 M. This is 99.93% lower than that of the Pharmaceuticals sector and 99.79% lower than that of the Health Care industry. The current liabilities for all United States stocks is 99.99% higher than that of the company.
Acasti Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acasti Pharma's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Acasti Pharma could also be used in its relative valuation, which is a method of valuing Acasti Pharma by comparing valuation metrics of similar companies.Acasti Pharma is currently under evaluation in current liabilities category among its peers.
Acasti Fundamentals
Return On Equity | -0.19 | |||
Return On Asset | -0.12 | |||
Current Valuation | 11.17 M | |||
Shares Outstanding | 10.14 M | |||
Shares Owned By Insiders | 38.39 % | |||
Shares Owned By Institutions | 21.22 % | |||
Number Of Shares Shorted | 154.19 K | |||
Price To Earning | 15.34 X | |||
Price To Book | 0.58 X | |||
Price To Sales | 208.39 X | |||
Gross Profit | 120 K | |||
EBITDA | (11.3 M) | |||
Net Income | (12.85 M) | |||
Cash And Equivalents | 38.39 M | |||
Cash Per Share | 0.86 X | |||
Total Debt | 11.56 M | |||
Debt To Equity | 0.01 % | |||
Current Ratio | 11.13 X | |||
Book Value Per Share | 5.86 X | |||
Cash Flow From Operations | (12.33 M) | |||
Short Ratio | 3.84 X | |||
Earnings Per Share | (1.43) X | |||
Target Price | 7.97 | |||
Beta | 1.52 | |||
Market Capitalization | 36.5 M | |||
Total Asset | 73.3 M | |||
Retained Earnings | (211.12 M) | |||
Working Capital | 22.33 M | |||
Current Asset | 11.33 M | |||
Current Liabilities | 1.14 M | |||
Net Asset | 73.3 M |
About Acasti Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acasti Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acasti Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acasti Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Other Consideration for investing in Acasti Stock
If you are still planning to invest in Acasti Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acasti Pharma's history and understand the potential risks before investing.
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |